Elevance Health (ELV) 8-K Current Report: February 26, 2026
Filed: February 26, 2026
Financials
Hospital & Medical Service PlansElevance Health (ELV) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
Elevance Health 8-K Feb 26, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • Peter Haytaian exits EVP/President of Carelon role effective May 4, 2026, citing family commitments — not a dispute-driven departure
- • Transitions to Special Advisor through Dec 31, 2026, providing ~8-month runway for leadership transition at Carelon
- • Carelon is Elevance's health services segment — leadership continuity here is material given its strategic growth priority
- • No successor named in this filing; investor focus should shift to Exhibit 99.1 press release for replacement details
Item 7.01 · Regulation FD Disclosure
- • Reg FD disclosure: forward-looking statement boilerplate only — no financial data, guidance, or material new information disclosed
- • Key risk factors flagged: healthcare cost trends, Medicare/Medicaid compliance, CMS Star Ratings, cyber threats, and AI system failures
- • Elevated sector-specific risks noted: negative industry sentiment (post-UnitedHealthcare event context) and pharmacy services agreement with CaremarkPCS Health
- • Shareholder return risks highlighted: dividend restrictions, share repurchase capacity, and substantial outstanding debt load all cited as potential constraints
Other Elevance Health 8-K Filings
Get deeper insights on Elevance Health
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.